These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26096679)

  • 41. Modulating GPR40: therapeutic promise and potential in diabetes.
    Poitout V; Lin DC
    Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
    J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release.
    Cione E; Caroleo MC; Kagechika H; Manetti F
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):377-383. PubMed ID: 33525941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacophore-based design of novel oxadiazoles as selective sphingosine-1-phosphate (S1P) receptor agonists with in vivo efficacy.
    Quattropani A; Sauer WH; Crosignani S; Dorbais J; Gerber P; Gonzalez J; Marin D; Muzerelle M; Beltran F; Nichols A; Georgi K; Schneider M; Vitte PA; Eligert V; Novo-Perez L; Hantson J; Nock S; Carboni S; de Souza AL; Arrighi JF; Boschert U; Bombrun A
    ChemMedChem; 2015 Apr; 10(4):688-714. PubMed ID: 25735812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, Synthesis, and Structure-Activity Relationship Studies of (4-Alkoxyphenyl)glycinamides and Bioisosteric 1,3,4-Oxadiazoles as GPR88 Agonists.
    Rahman MT; Decker AM; Langston TL; Mathews KM; Laudermilk L; Maitra R; Ma W; Darcq E; Kieffer BL; Jin C
    J Med Chem; 2020 Dec; 63(23):14989-15012. PubMed ID: 33205975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
    Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
    J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents.
    Hu Y; Lu X; Chen K; Yan R; Li QS; Zhu HL
    Bioorg Med Chem; 2012 Jan; 20(2):903-9. PubMed ID: 22192936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles.
    Tolmachev A; Bogolubsky AV; Pipko SE; Grishchenko AV; Ushakov DV; Zhemera AV; Viniychuk OO; Konovets AI; Zaporozhets OA; Mykhailiuk PK; Moroz YS
    ACS Comb Sci; 2016 Oct; 18(10):616-624. PubMed ID: 27548754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions.
    Lu SY; Jiang YJ; Lv J; Wu TX; Yu QS; Zhu WL
    J Mol Graph Model; 2010 Jun; 28(8):766-74. PubMed ID: 20227312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
    Scott JS; Bowker SS; Brocklehurst KJ; Brown HS; Clarke DS; Easter A; Ertan A; Goldberg K; Hudson JA; Kavanagh S; Laber D; Leach AG; MacFaul PA; Martin EA; McKerrecher D; Schofield P; Svensson PH; Teague J
    J Med Chem; 2014 Nov; 57(21):8984-98. PubMed ID: 25286150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition.
    Tikhonova IG; Sum CS; Neumann S; Thomas CJ; Raaka BM; Costanzi S; Gershengorn MC
    J Med Chem; 2007 Jun; 50(13):2981-9. PubMed ID: 17552505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.
    Stasi LP; Artusi R; Bovino C; Buzzi B; Canciani L; Caselli G; Colace F; Garofalo P; Giambuzzi S; Larger P; Letari O; Mandelli S; Perugini L; Pucci S; Salvi M; Toro P
    Bioorg Med Chem Lett; 2013 May; 23(9):2653-8. PubMed ID: 23535328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Theoretical analysis of solvent effects on nitrogen NMR chemical shifts in oxazoles and oxadiazoles.
    Ksiazek A; Borowski P; Wolinski K
    J Magn Reson; 2009 Apr; 197(2):153-60. PubMed ID: 19135396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A rapid screening for cytochrome P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives.
    Tsotsou GE; Di Nardo G; Sadeghi SJ; Fruttero R; Lazzarato L; Bertinaria M; Gilardi G
    J Biomol Screen; 2013 Feb; 18(2):211-8. PubMed ID: 22983164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A metal-free route to 2-aminooxazoles by taking advantage of the unique ring opening of benzoxazoles and oxadiazoles with secondary amines.
    Joseph J; Kim JY; Chang S
    Chemistry; 2011 Jul; 17(30):8294-8. PubMed ID: 21656592
    [No Abstract]   [Full Text] [Related]  

  • 56. Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1.
    Gasser A; Brogi S; Urayama K; Nishi T; Kurose H; Tafi A; Ribeiro N; Désaubry L; Nebigil CG
    PLoS One; 2015; 10(4):e0121027. PubMed ID: 25831128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.
    Zhou C; Tang C; Chang E; Ge M; Lin S; Cline E; Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger J; Howard AD; Thornberry N; Mills SG; Yang L
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1298-301. PubMed ID: 20064714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
    Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
    ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
    [No Abstract]   [Full Text] [Related]  

  • 59. Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.
    Bansal S; Bala M; Suthar SK; Choudhary S; Bhattacharya S; Bhardwaj V; Singla S; Joseph A
    Eur J Med Chem; 2014 Jun; 80():167-74. PubMed ID: 24780593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
    Adam JM; Clark JK; Davies K; Everett K; Fields R; Francis S; Jeremiah F; Kiyoi T; Maidment M; Morrison A; Ratcliffe P; Prosser A; Schulz J; Wishart G; Baker J; Boyce S; Campbell R; Cottney JE; Deehan M; Martin I
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2932-7. PubMed ID: 22421020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.